Advanced Catheter Therapies, Inc. (ACT) is an early stage research and development medical device company with a portfolio of innovative catheter technologies targeting vascular disease including thrombosis, inflammation, occlusions and restenosis.

ACT has initially focused its resources on the problem of restenosis and is developing the game-changing Occlusion Perfusion Catheter™ (OPC™). The OPC is a multi‐lumen balloon catheter designed to temporarily occlude a specific region from blood flow to allow the local delivery of therapeutic agents to the peripheral and coronary vasculature.

Also in the development pipeline are devices to improve endovascular debulking procedures (the clearing of blocked blood vessels).

CHATTANOOGA, TN, January 10, 2012 – Advanced Catheter Therapies, Inc. (ACT), (www.acatheter.com) today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8088103 for its catheter technology. The company recently announced a name change from Atlanta Catheter Therapies.

The patent, entitled "Occlusion Perfusion Catheter,” was issued on January 3, 2012. The Occlusion Perfusion Catheter ™ (OPC™) is a multi‐lumen balloon catheter designed to temporarily occlude a specific region from blood flow to allow the local delivery of therapeutic agents to the peripheral and coronary vasculature. Also in the company’s development pipeline are devices to improve endovascular debulking procedures (the clearing of blocked blood vessels).